share_log

Ocugen To Participate In Fireside Chat At Cantor Global Healthcare Conference Sept. 28 at 8 a.m. EDT

Ocugen To Participate In Fireside Chat At Cantor Global Healthcare Conference Sept. 28 at 8 a.m. EDT

Ocugen將參加9月9日Cantor全球醫療會議的爐邊聊天28日上午8點EDT
Benzinga Real-time News ·  2021/09/23 16:19

Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that its Chairman, CEO, and Co-Founder, Dr. Shankar Musunuri, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8 a.m. Eastern Time. Dr. Musunuri will discuss COVAXIN™, the investigational COVID-19 vaccine which the company is co-developing with Bharat Biotech for the U.S. and Canadian markets. He will also present information about Ocugen’s breakthrough modifier gene therapy platform, which has generated product candidates that are expected to enter Phase 1/2a clinical trials in ophthalmic disease states over the next 18 months.

專注於發現、開發和商業化治療失明疾病的基因療法和對抗新冠肺炎的疫苗的生物製藥公司歐庫根公司(納斯達克市場代碼：OCGN)今天宣佈，其董事長、首席執行官兼聯合創始人尚卡爾·穆蘇努裏博士將出席2021年9月28日(星期二)上午8點舉行的2021年坎託虛擬全球醫療大會。東部時間。穆蘇努裏博士將討論COVAXIN™，這是該公司與巴拉特生物技術公司在美國和加拿大市場共同開發的一種新冠肺炎研究疫苗。他還將介紹歐庫根公司突破性的修飾劑基因治療平台的信息，該平台已經產生了候選產品，預計將在未來18個月內進入眼科疾病狀態的1/2a期臨牀試驗。

The fireside chat can be viewed live at https://wsw.com/webcast/cantor12/ocgn/2072070 and will be available within Ocugen’s Investor Relations page found at https://ir.ocugen.com.

爐邊談話可在https://wsw.com/webcast/cantor12/ocgn/2072070網站上現場觀看，並可在歐庫根公司投資者關係頁面上觀看，網址為https://ir.ocugen.com.。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論